They have $2M in assets left and they haven't reported 4th quarter losses. They have lost $2M each quarter since 2010, the company is bankrupt. Orphan designation means absolutely nothing, they haven't even finished testing. Stock has a book value of 0.76.
many years away, they need to raise many millions for Ph 3 clinical trial, if it makes it that far, still enrolling Phase 2...have enough money currently to last until end of March 2013. Equity raise is imminent.